This is the only quantitative PCR-based panel of its kind on the market that distinguishes between CALR Type 1 and Type 2 alongside the other genes relevant to the molecular evaluation of MPN.

Mutations of type 1 (52-bp deletion; c.1092_1143del) and mutations of type 2 (5-bp insertion; c.1154_1155insTTGTC) accounted for 53.0% and 31.7% of all the cases with mutated CALR, respectively ...

Among others, new mutations have been identified such as CALR type 1 and type 2. ... ASH: CALR mutations ID'd in myeloproliferative neoplasms. Dec 10, 2013.

Although ET is a rare disease, cases have been reported where patients have the condition with MPL and Type 1 calreticulin (CALR) gene mutations. In the current case study, ...

NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a ...

--Specialty cancer diagnostics company Precipio, Inc. announces the launch of a new version of its Bloodhound MPN panel that is now able to distinguish between CALR type 1 and type 2 mutations.

NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN ...

NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative ...

Detailed price information for Precipio Inc (PRPO-Q) from The Globe and Mail including charting and trades.